ArriVent BioPharma (NASDAQ:AVBP) Price Target Cut to $27.00 by Analysts at HC Wainwright

ArriVent BioPharma (NASDAQ:AVBP) had its price target reduced by equities researchers at HC Wainwright from $47.00 to $27.00 in a report issued on Thursday, Marketbeat reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 59.86% from the stock’s current price.

Several other research analysts have also recently commented on the stock. Guggenheim lowered their target price on shares of ArriVent BioPharma from $45.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday. BTIG Research cut their price target on ArriVent BioPharma from $42.00 to $29.00 and set a “buy” rating for the company in a research note on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a research report on Friday, July 17th. Citigroup lowered their price objective on ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Truist Financial dropped their price objective on ArriVent BioPharma from $45.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $27.44.

ArriVent BioPharma Stock Performance

Shares of ArriVent BioPharma stock opened at $16.89 on Thursday. The firm has a 50-day moving average of $29.30 and a 200-day moving average of $29.39. The stock has a market cap of $832.85 million, a PE ratio of -4.67 and a beta of 1.34. ArriVent BioPharma has a 52-week low of $11.36 and a 52-week high of $35.83.

ArriVent BioPharma (NASDAQ:AVBP) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.06). Equities research analysts predict that ArriVent BioPharma will post -4.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ArriVent BioPharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tidal Investments LLC acquired a new stake in shares of ArriVent BioPharma during the 2nd quarter worth approximately $1,981,000. Engineers Gate Manager LP bought a new stake in ArriVent BioPharma during the second quarter worth $773,000. Arizona State Retirement System acquired a new stake in shares of ArriVent BioPharma in the 2nd quarter valued at $233,000. Montanova Capital LLC boosted its holdings in shares of ArriVent BioPharma by 2.6% in the 2nd quarter. Montanova Capital LLC now owns 4,515,531 shares of the company’s stock valued at $156,870,000 after purchasing an additional 114,448 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of ArriVent BioPharma by 28.9% during the 2nd quarter. Wellington Management Group LLP now owns 100,855 shares of the company’s stock worth $3,504,000 after buying an additional 22,642 shares in the last quarter. 9.48% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Despite the trial failure, Citigroup and JonesTrading retained “buy” ratings on ArriVent, lowering their price targets to $20 and $22, respectively. Those targets imply potential upside from the reported share price, although they reflect substantially reduced expectations. Analyst price-target reports
• Neutral Sentiment: Trading in AVBP was temporarily halted for news pending on October 6, underscoring the significance of the clinical announcement and the resulting volatility. ArriVent FURVENT program update
• Negative Sentiment: ArriVent reported that the Phase 3 FURVENT trial of firmonertinib in previously untreated EGFR exon 20 insertion-mutant non-small cell lung cancer failed to meet its primary progression-free-survival endpoint. The company is reviewing the program’s future, raising concerns about its lead asset, regulatory prospects and commercial outlook. ArriVent late-stage trial setback
• Negative Sentiment: Reports indicated that AVBP shares fell roughly 48% to 60% and reached an all-time or one-year low as investors reassessed the company following the trial miss. The decline reflects the loss of confidence in firmonertinib as the central value driver. ArriVent shares plunge after FURVENT failure
• Negative Sentiment: Levi & Korsinsky, SBS Law and SueWallSt announced investigations or potential securities claims involving ArriVent. These notices do not establish wrongdoing, but they add legal and reputational risk after the sharp selloff and scrutiny of the company’s recent $250 million at-the-market offering. SBS Law ArriVent investigation

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.